Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DERIVE: PK of Atazanavir with Rifampicin in HIV+ Adults
NCT04121195Phase 3Completed
- Sponsor
- University of Liverpool
- Start
- Oct 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atazanavir in human immunodeficiency virus infection (HIV), sponsored by University of Liverpool. Primary endpoints: Plasma Cmax of ritonavir-boosted Atazanavir at 18 months, Plasma AUC of ritonavir-boosted Atazanavir at 18 months and 2 more. Started Oct 2020; status: completed.
02
Drugs
atazanavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04121195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121195.